KPT-276

1 Cited Publications
Kundenbewertung

Based on 1 publication(s) in Google Scholar

KPT-276 is an orally active and blood-brain barrier-penetrant selective XPO1/CRM1 inhibitor. KPT-276 blocks XPO1-mediated nuclear export function and promotes nuclear retention of various tumor suppressor proteins. KPT-276 induces apoptosis and G1 cell cycle arrest in tumor cells, and downregulates c-MYC, CDC25A, and BRD4. KPT-276 reduces immune cell proliferation through nuclear accumulation of cell cycle inhibitors, rescues TDP-43 cytoplasmic mislocalization, and restores axon growth and growth rate in mutant PFN1 motor neurons. KPT-276 maintains axonal cytoskeletal integrity and mitochondrial function, and inhibits tumor growth. KPT-276 can be used for research on glioblastoma, non-Hodgkin lymphoma, amyotrophic lateral sclerosis, multiple myeloma, and non-small cell lung cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

  • Reinheit : 99.94%
  • CAS. Nr.: 1421919-75-6
  • Formel: C16H10F8N4O
  • Molecular Weight:426.26
  • Speicherung:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • Biologische Aktivität
  • Chemical Information
  • Lösungsmittel & Löslichkeit
  • Protokoll
  • Reinheit & Dokumentation
  • Verweise
  • Help & FAQs

Publications Citing Use of MedChemExpress (MCE) KPT-276

More

Alle Epigenetic Reader Domain Isoform-spezifische Produkte anzeigen

More

Alle Interleukin Related Isoform-spezifische Produkte anzeigen

More
MOQ
Minimum order quantity
100 mg

Angebot einholen Auf Lager

Other size
Angebot einholen
Please select quantity
Amount: USD 0.00